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ABSTRACT
Purpose Gemcitabine is the standard chemotherapy for
patients with metastatic pancreatic adenocarcinoma.
Although the 5-ﬂuorouracil (5FU), folinic acid and
cisplatin combination (LV5FU2-CDDP) is an option, the
optimal order of the regimens must be determined. The
ﬁrst strategic phase III trial comparing LV5FU2-CDDP
followed by gemcitabine versus gemcitabine followed by
LV5FU2-CDDP was conducted.
Methods Patients with metastatic pancreatic
adenocarcinoma, performance status (PS) 0e2, without
prior chemotherapy were randomly assigned (1:1) to
receive either LV5FU2-CDDP followed by gemcitabine at
disease progression or toxicity (Arm A), or the opposite
sequence (Arm B). 202 patients had to be included and
170 deaths had to be observed to detect an expected
improvement in median overall survival (OS) from 6.5 to
10 months in Arm A (two-sided a ¼ 5% and b ¼ 20%).
Results 202 patients were included (Arm A, 102; Arm
B, 100). Median age, male/female ratio, PS 0e1 and
previous surgery were similar in the two arms. After
a median follow-up of 44 months, median OS in Arm A
was 6.6 months versus 8.0 months in Arm B (p ¼ 0.85).
Median progression-free survival was similar between
Arms A and B. More grade 3/4 toxicities were observed
when LV5FU2-CDDP was administered as a ﬁrst-line
treatment compared with gemcitabine: 79% versus 64%
(p ¼ 0.018).
Conclusion This trial did not show any strategic
advantage to using LV5FU2-CDDP as a ﬁrst-line
treatment and suggests that gemcitabine remains the
standard ﬁrst-line treatment. Sixty-one per cent of
patients were able to receive a second line of
chemotherapy.
INTRODUCTION
Pancreatic adenocarcinoma is a highly malignant
disease, representing the ﬁfth most common cause
of death from cancer in western countries, with
<5% of patients still living at 5 years. Only
10e20% of patients are eligible for surgery at
diagnosis and approximately half of the remaining
patients have a non-resectable tumour.
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Signiﬁcance of this study
What is already known about this subject?
< After the study by Burris et al, gemcitabine-
based chemotherapy became the gold standard
for systemic treatment of advanced pancreatic
cancer.
< Most of the subsequent randomised trials
comparing gemcitabine with gemcitabine
combined with chemotherapy or biotherapy
failed to demonstrate a clinical beneﬁt.
< This study tries to answer the question of an
intensiﬁed ﬁrst-line treatment.
< The role of a second line of treatment for
metastatic cancer remained debated and there
is no standard in patients with metastatic
pancreatic adenocarcinoma that progresses
after gemcitabine-based ﬁrst-line treatment.
What are the new ﬁndings?
< This is the ﬁrst controlled trial to evaluate
systematic second-line chemotherapy in
patients with disease progression after the
ﬁrst line and its possible inﬂuence on overall
survival (OS).
< This randomised multicentre phase III trial was
designed to compare OS for both therapeutic
sequences.
< No signiﬁcant difference in either progression-
free survival or OS was observed between the
two treatment arms.
How might it impact on clinical practice in the
foreseeable future?
< Gemcitabine was better tolerated when admin-
istrated as a ﬁrst-line treatment and remains the
standard ﬁrst-line treatment.
< A high percentage of patients were able to
receive second-line chemotherapy in this study.
< A platinum-based regimen could be used for
second-line treatment.
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PancreasAfter the study by Burris et al.
2 showing that gemcitabine-based
chemotherapy was more effective than bolus 5-ﬂuorouracil (5FU),
the former became the gold standard for systemic treatment of
advanced pancreatic cancer. However, the median survival is still
only 5.6 months.
2 Numerous studies have tried to increase the
efﬁcacy of chemotherapy by combining gemcitabine with others
drugs, but none of the regimens evaluated in phase III trials has
shown an increase in overall survival (OS).
3e9 Only one rando-
mised trial including 569 patients comparing gemcitabine with
gemcitabine combined with erlotinib showed a modest but
signiﬁcant increase in OS in the erlotinib arm (6.24 months vs
5.91 months) when gemcitabine was combined with erlotinib.
10
Cisplatin combined with 5FU appears promising in metastatic
pancreatic carcinoma, with a 26% response rate with a median
survival of 7 months in a phase II trial.
11 In a randomised trial
comparing 5FU with 5FU plus cisplatin, FU-CDDP was better
than FU for response and progression-free survival (PFS) but not
OS.
12 However, this regimen had serious toxic side effects. A
phase II study using a combination of 5FU plus cisplatin with
a bimonthly LV5FU2-cisplatin schedule (LV5FU2-CDDP) was
better tolerated with a promising OS (9 months).
13 As a result,
we compared this regimen with gemcitabine alone as ﬁrst-line
treatment. In addition we wanted to explore the role of a second
line of treatment for this cancer.
This paper reports the ﬁnal results of this FFCD (Fédération
Francophone de Cancérologie Digestive) phase III trial
comparing two successive lines of chemotherapy.
PATIENTS AND METHODS
Patient selection
Eligibility criteria were: proven metastatic pancreatic adenocar-
cinoma by histological or cytological biopsy, at least one
measurable metastasis $10 mm on CTor MRI or $20 mm with
a conventional scan. The targeted metastasis should not have
been treated by radiotherapy. All patients gave written informed
consent to participate, were over 18, had a WHO performance
status (PS) #2 and a life expectancy of >2 months. Adequate
bone marrow (absolute neutrophil count (ANC) $1.5 3 10
9/l,
platelets $100 3 10
9/l), liver function (total bilirubin
< 50 mmol/l, alkaline phosphatases < 3ULN (upper limit if
normal), previous biliary stenting was allowed) and renal func-
tion (creatinine clearance >60 ml/min) were required.
Exclusion criteria were: previous palliative or adjuvant
chemotherapy, prior radiotherapy <4 weeks, brain metastases,
a medical history of malignant tumours, pregnant women or
woman who were breast feeding, and locally advanced cancer
with no evidence of metastases.
The protocol was approved by the Regional Ethics Committee
(Marseille, France).
Study design and randomisation
Clinical and biological investigation
Pretreatment evaluation included a full medical history, physical
examination, haematological and biochemical analysis,
including quality of life (QoL) with the EORTC QLQ-C30
(European Organization for Research and Treatment of Cancer
Quality of Life Questionnaire-C30).
All eligible patients were randomised 1:1 through a mini-
misation program at the FFCD centre (Dijon): to either Arm A,
LV5FU2-CDDP followed by gemcitabine after progression; or
Arm B, gemcitabine followed by LV5FU2-CDDPafter progression.
Patients were stratiﬁed according to WHO PS (0, 1 vs 2),
tumour localisation (head vs other) and participating institutions
(centre).
Treatment plan
LV5FU2-CDDP included a 2 h infusion of leucovorin (LV)
200 mg/m
2 followed by 5FU as a bolus 400 mg/m
2 then a 46 h
infusion of 2400 mg/m
2 with cisplatin 50 mg/m
2 as a 2 h infusion
on day 1, every 2 weeks.
Gemcitabine included 1000 mg/m
2 as a 30 min weekly infu-
sion for 7/8 weeks and then a weekly infusion for 3/4 weeks
according to a classic Burris regimen.
In the case of disease progression during the ﬁrst line of
treatment, second-line chemotherapy was initiated until
progression occurred.
Dose adjustment
If grade 3 or 4 toxicity occurred treatment was interrupted until
toxicity had decreased to #grade 2. Treatment was then begun
again with a 25% reduction in the initial dosage. If grade 3 or 4
toxicity occurred again treatment was discontinued. Recovery of
renal function to grade 0 was necessary to continue cisplatin
with a 25% dose reduction.
Evaluation and follow-up
All toxicities were graded according to National Cancer Institute
common toxicity (NCI-CTC) criteria (v3.0). Serious adverse
events were also recorded within 24 h.
After randomisation, a complete clinical examination and full
laboratory investigations were performed every 2 weeks. Plate-
lets, white blood cells (WBC) and haemoglobin were collected
each week from patients receiving gemcitabine.
Radiological assessment (abdominal and thoracic CT scan)
and tumour marker (carcinoembryonic antigen (CEA) and
cancer antigen (CA) 19-9) evaluations were performed every
8 weeks. The tumour response was classiﬁed according to
RECIST (Response Evaluation Criteria In Solid Tumors) criteria
based on imaging results. After ending treatment, follow-up
information including a clinical examination and QoL assess-
ment was available for all patients every 8 weeks until disease
progression or death.
Statistical methods
This randomised multicentre phase III trial was designed to
compare OS as the primary end point. OS was deﬁned as the
interval between randomisation and death (all causes). To detect
an expected improvement in median OS from 6.5 (Arm B) to
10 months in arm A (two-sided a ¼ 5% and b ¼ 20%), 202
patients had to be included over 32 months (including 5% of lost
to follow-up) to observe 170 deaths. The minimum follow-up
for the last included patient was 13 months.
Secondary end points included:
e PFS was deﬁned as the interval between randomisation and
the ﬁrst disease progression or death (all causes). Patients alive
without progression were censored.
e Second-line PFS (PFS2) was deﬁned as the interval between
randomisation and progression or death (all cause) during
second-line treatment. Patients alive without progression
during second-line treatment were censored. In patients
receiving only one line of treatment, PFS2 was deﬁned as the
interval between randomisation and the ﬁrst disease progression
or death (all causes).
e Proportion of patients receiving a second line.
e Tolerance for each line.
e The results of QoL assessed by EORTC QLQ-C30 will be
presented in a later publication.
All analyses were performed on a strict intent to treat prin-
ciple. The safety population, deﬁned as all patients receiving at
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was used to compare toxicities.
Qualitative and continuous variables were described using
percentage, means (SD) and medians (minimum e maximum),
respectively, and then compared using the c
2 or Fisher exact test
and the ManneWhitney test, respectively. Median follow-up
was calculated according to the reverse KaplaneMeier estimates.
Survival curves were plotted using KaplaneMeier estimates and
were compared using log-rank tests and stratiﬁed log-rank tests.
The unstratiﬁed and stratiﬁed univariate Cox models were used
to calculate the HR with a 95% CI. All analyses were performed
using Stata software (V10; StataCorp, College Station, Texas,
USA) at the 0.05 level of signiﬁcance.
RESULTS
Between August 2003 and May 2006, in 33 French centres, 102
patients and 100 patients were included in Arm A (ﬁrst-line
LV5FU2-CDDP) and Arm B (ﬁrst-line gemcitabine), respectively.
Three patients in Arm B did not meet the major inclusion
criteria and had received prior chemotherapy (two adjuvant and
one palliative chemotherapy). Twenty-six patients and 24
patients did not meet minor biological or haematological eligi-
bility criteria in Arms A and B, respectively, and three patients
were lost to follow-up in Arm A. However, the 202 patients
were included in the intent to treat analyses (ﬁgure 1). The
median follow-up was 44 months.
Patient characteristics
Patient characteristics are summarised in table 1. Arms A and B
were well matched. In Arms A and B the median age was 62 and
65 years and WHO PS 0e1 was 77% and 83%, respectively. Sex,
biological markers, prior treatments, and sites of metastases
were well balanced. However, one patient in Arm A and two
patients in Arm B had received radiotherapy >4 weeks before
randomisation. Mean CEA and CA 19-9 levels were also similar
in each arm
Treatment delivery
One patient in Arm A and four patients in Arm B did not receive
at least one dose of chemotherapy due to complications.
As shown in table 2, the median duration of ﬁrst-line treat-
ment was signiﬁcantly longer in patients receiving gemcitabine
than in those receiving LV5FU2-CDDPas the ﬁrst-line treatment:
10 weeks versus 5 weeks (p ¼ 0.0001). Furthermore, the median
duration of second-line treatment was signiﬁcantly longer in
patients receiving gemcitabine than in those receiving LV5FU2-
CDDP as a second-line treatment: 8 versus 4 weeks (p ¼ 0.044)
Toxicity
The distribution of maximum grade 3/4 toxicities in each arm
according to the line of chemotherapy is shown in table 3. This
table shows signiﬁcant differences in haematological grade 3/4
toxicities when LV5FU2-CDDP was administered as the ﬁrst
line of treatment compared with gemcitabine as the ﬁrst line:
50% in Arm A versus 35% in Arm B (p ¼ 0.03). While no
differences were observed for non-haematological and nausea/
vomiting grade 3/4 toxicities, the occurrence of all grade 3/4
toxicities was signiﬁcantly more frequent when LV5FU2-CDDP
rather than gemcitabine was administered as the ﬁrst line of
treatment: 79% in Arm A versus 64% in Arm B (p ¼ 0.018).
Figure 1 CONSORT diagram. Assessed for enrolment
(n = 202)
202 patients 
randomly 
assigned
Intent to treat 
population data set 
Excluded (n = 0)
Allocated to Arm A 
n = 102 
Patients receiving at least one 
cycle  
of LV5FU2-CDDP: n = 101 
Patients receiving a second line 
Lost of follow up: n = 3
Reason for second line 
receiving (n=69) :   
- Disease progression : n = 45 
- Other : n  = 15 
- Unknown: n = 9 
Enrolment
Analyzed n = 102 pts 
Follow up
Allocation
Outcome 
analysis 
Major ineligibility criteria: 
n = 0 
Minor ineligibility criteria 
ANC < 1500: n = 3  
PAL > 5N : n = 7   
Bilirubin > 50 : n =  6 
Creatinin clearance < 60: n = 11 
Analyzed n = 100 pts 
Lost of follow up: n = 0
Reason for second line 
receiving (n=55) :   
- Disease progression : n = 48 
- Other : n  = 4 
- Unknown: n = 3 
Allocated to Arm B
n = 100 
Patients receiving at least one 
cycle  
Of gemcitabine: n = 96 
Patients receiving a second line 
Major ineligibility criteria: 
Prior chemotherapy: n = 3 
Minor ineligibility criteria 
ANC < 1500: n = 2  
PAL > 5N : n = 10   
Bilirubin > 50 : n =  4 
Creatinin clearance < 60: n = 10 
N = 69 N = 55
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gemcitabine was administered as the second line compared with
LV5FU2-CDDP: 58% in Arm A versus 33% in Arm B (p ¼ 0.004)
probably because of a decline of the bone marrow due an
intensiﬁed ﬁrst line. In contrast, nausea/vomiting grade 3/4
toxicities tended to be less frequent in Arm A: 4% versus 15% in
Arm B (p ¼ 0.065).
In patients receiving two lines of treatment (69 patients in
Arm A and 55 patients in Arm B) signiﬁcantly (p ¼ 0.007) more
grade 3/4 haematological toxicities were observed when gemci-
tabine was administered as the second line (arm A) (n¼40, 58%)
than with gemcitabine as the ﬁrst line (Arm B) (n¼19, 35%).
Occurrence of all grade 3/4 toxicities was also signiﬁcantly
(p¼ 0.017) more frequent when gemcitabine was administered
as a second line: 74% in Arm A (N¼51) versus 55% in Arm B
(N¼30). However, no differences were observed for non-
haematological or nausea/vomiting grade 3/4 toxicities.
In contrast, there were signiﬁcantly (p ¼ 0.004) more grade 3/
4 haematological toxicities when LV5FU2-CDDP was adminis-
tered as the ﬁrst-line treatment (n¼41, 59%) than with LV5FU2-
CDDP administered as a second-line treatment (n¼18, 33%). No
differences were observed for non-haematological and nausea/
vomiting grade 3/4 toxicities, resulting in no signiﬁcant differ-
ences in grade 3/4 toxicities (p ¼ 0.16) when LV5FU2-CDDP
was administered as second or ﬁrst line of treatment: 81% in
Arm A (n¼56) versus 69% in Arm B (n¼38).
Number of patients receiving second-line treatment
Table 4 shows that 69 patients (68%) and 55 patients (55%)
received a second line of chemotherapy in Arms A and B,
respectively (non-signiﬁcant). However, the reasons for the
second line of chemotherapy were mainly (p ¼ 0.006) due to
progression in Arm B (48 patients, 87%) compared with Arm A
(45 patients, 65%). Other reasons for changing the ﬁrst line of
treatment were toxicity in 12 patients in Arm A (17%) and 3
patients in Arm B (6%) (p ¼ 0.006). Others reasons in Arm A
were a poor general condition (1 patient), stroke (1patient),
weight loss (1 patient) and unknown (9 patients). Other reasons
in Arm B were pain (1 patient) and unknown causes (3 patients).
Table 1 Patients’ demographics and clinical characteristics.
Arm A (LV5FU2-
CDDP in ﬁrst line)
Arm B
(gemcitabine in
ﬁrst line)
n% n%
Patients 102 100
Female sex 37 36 35 36
WHO PS
02 8 2 7 3 0 3 0
15 1 5 0 5 3 5 3
22 2 2 1 1 4 1 4
Not determined 1 1 3 3
Primary tumour location
Head 57 56 49 49
Other 44 43 50 50
Unknown 1 1 1 1
Site of metastases
Liver 87 85 90 90
Lung 15 15 12 12
Lymph nodes 18 18 24 24
Peritoneum 11 11 17 17
Other 7 7 8 8
Prior treatment
Chemotherapy 0 0 3 3
Radiotherapy 1* 1 2* 2
Surgery 23 23 27 27
Resection 13 57 14 40
Drainage 4 17 8 30
Others 6 26 6 22
Radiological/endoscopic drainage 22 22 11 11
Duodenal stenting 10 10 5 5
Age (years) Median (minemax)
62 (40e84)
Median (minemax)
65 (39e81)
Biological tumorous marker
CEA (ng/ml) 9 (0e2224) 7(1e3604)
CA 19-9 (UI/ml) 565(0e862200) 560(1e156649)
*Radiotherapy >4 weeks before randomisation.
CA 19-9, cancer antigen 19-9; CEA, carcinoembryonic antigen; LV5FU2-CDDP,
5-ﬂuorouracil, folinic acid and cisplatin combination; PS, performance status.
Table 2 Treatment administration
LV5FU2-CDDP Gemcitabine p Value*
Line 1 Arm A Arm B
N ¼ 102 N ¼ 100
Patients with at least 1 administration 101(99%) 96 (96%) 0.21
Median duration of treatment
in weeks (n ¼ 96)
5 (0.1e96)
(n ¼ 96)
10 (1e64)
(n ¼ 93)
0.0001
Line 2 Arm B Arm A
N ¼ 100 N ¼ 102
Patients with at least one
administration
55(55%) 69 (68%) 0.11
Median duration of treatment
in weeks
4 (0.1e74)
(n ¼ 53)
8( 1 e21)
(n ¼ 63)
0.044
*All two-sided Fisher exact tests or Wilcoxon rank-sum (ManneWhitney) test.
LV5FU2-CDDP, 5-ﬂuorouracil, folinic acid and cisplatin combination.
Table 3 Toxicities according to WHO criteria
N LV5FU2-CDDP Gemcitabine p Value*
Line 1 Arm A Arm B
N¼101 N¼96
All toxicities 80 (79%) 61 (64%) 0.018
Haematological toxicities 50 (50%) 33 (35%) 0.03
Non-haematological toxicities 54 (53%) 44 (46%) 0.317
Nausea and vomiting 13 (13%) 8 (8%) 0.359y
Line 2 Arm B Arm A
N¼55 N¼69
All toxicities 38 (69%) 51(74%) 0.476
Haematological toxicities 18 (33%) 40 (58%) 0.004
Non-haematological toxicities 28 (51%) 35 (51%) 0.828
Nausea and vomiting 8 (15%) 3 (4%) 0.065y
Overall toxicities (lines 1 and 2) Arm A Arm B
N¼101 N¼96
All toxicities 87 (86%) 77 (80%) 0.256
Haematological toxicities 60 (59%) 41 (43%) 0.015
Non-haematological toxicities 70 (69%) 60 (63%) 0.311
Nausea and vomiting 14 (14%) 15 (16%) 0.748
Toxicities grade 3/4 Line 1 Line 2 p
LV5FU2-CDDP Arm A Arm B
N¼69 N¼55
All toxicities 56 (81%) 38 (69%) 0.16
Haematological toxicities 41 (59%) 18 (33%) 0.004
Gemcitabine Arm B Arm A
N¼55 N¼69
All toxicities 30 (55%) 51(74%) 0.017
Haematological toxicities 19 (35%) 40 (58%) 0.007
*All two side Pearson tests without missing value modality.
yAll two-sided Fisher exact tests.
LV5FU2-CDDP, 5-ﬂuorouracil, folinic acid and cisplatin combination.
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progression in 44 patients (64%) in Arm A and 34 patients (62%)
in Arm B.
Best response during treatment
During the ﬁrst line of treatment in Arm A, 15 patients had an
objective response (3 complete responses and 12 partial
responses). In arm B, 19 patients had an objective response (3
complete responses and 16 partial responses).(table 4)
During the second line of treatment, 7 patients had a partial
response in Arm A and 4 patients had an objective response (1
complete response, 3 partial responses) in Arm B.
Overall, 19 patients had an objective response (3 complete
responses, 16 partial responses) and 39 patients had stable
disease in Arm A while 22 patients had an objective response (4
complete responses, 18 partial responses) and 37 patients had
stable disease in Arm B. We observed 24 and 17 progressions in
Arms A and B, respectively, as the best response. No differences
were observed for tumour control according to ﬁrst or second
line of administration (table 4).
Overall survival
At the cut-off date, 192 patients had died, 94 (92%) and 98
(98%) in Arms A and B, respectively (table 4). As shown in
ﬁgure 2, OS did not differ with the treatment sequence (HR 0.97
(95% CI 0.73 to 1.29), log-rank p ¼ 0.83). Median OS was
6.7 months (95% CI 5.4 to 8.6) in Arm A and 8.03 months (95%
CI 5.9 to 9.8) in Arm B (ﬁgure 2).
The 1 year OS rate was 28.8% (95% CI 20.4% to 37.8%) in
Arm A and 32.7% (95% CI 23.7% to 42.0%) in Arm B, and the
2 year OS rate was 7.5% (95% CI 3.2% to 14.1%) in Arm A and
4.1% (95% CI 1.3% to 9.4%) in Arm B.
Progression-free survival
At the cut-off date, 69 patients (68%) and 68 patients (68%) had
disease progression in Arms A and B, respectively. Moreover,
30 patients in Arm A and 32 patients in Arm B died without
reported disease progression. The median PFS was 3.4 months
(95% CI 2.4 to 4.4) in arm A and 3.5 months (95% CI 2.4 to 4.1)
in Arm B (HR 1.06 (95% CI 0.8 to 1.4), log-rank p¼0.67)
(ﬁgure 3A).
Table 4 Response and survival to treament according to the group of treatment
LV5FU2-CDDP Gemcitabine
Arm A
N[102
Arm B
N[100
p Value n% n%
Best tumorous response in second line N¼ 69 N ¼ 55 0.8*
Complete response (CR) 0 0 1 2
Partial response 7 10 3 5
Stable disease 19 28 21 38
Progression 25 36 21 38
Not evaluable 0 0 1 2
Unknown 18 26 8 15
Best tumorous response in ﬁrst line N ¼ 102 N ¼ 100
Complete response (CR) 3 3 3 3
Partial response 12 12 16 16
Stable disease 33 32 29 29
Progression 27 27 25 25
Not evaluable 3 3 1 1
Unknown 24 24 26 26
Overall best tumorous response
Complete response (CR) 3 3 4 4
Partial response 16 16 18 18
Stable disease 39 38 37 37
Progression 24 23 17 17
Not evaluable 2 2 1 1
Unknown 18 18 23 23
Progression-free survival (PFS)
Median PFS in months (95% CI) 3.4 (2.4 to 4.4) 3.5 (2.4 to 4.1) 0.67y
Median PFS in months (95% CI) after
second line
5.03 (4.3 to 5.9) 5.8 (4.3 to 7.8) 0.61y
Overall survival (OS):
Median OS in months (95% CI) 6.7 (5.4 to 8.6) 8.03 (5.9 to 9.8) 0.83y
1 year OS 28.8% (20.4% to 37.8%) 32.7% (23.7% to 42.0%)
2 years OS 7.5% (3.2% to 14.1%) 4.1% (1.3% to 9.4%)
Death 94 92 98
Death without registered progression 30 29 32 32
Alive without registered progression 3 3 0 0
Second line
Patients receiving a second line 69 68 55 55 0.13*
Second line due to progression 45 65 48 87 0.006*
*c
2 or Fisher exact test.
yLog-rank test.
LV5FU2-CDDP, 5-ﬂuorouracil, folinic acid and cisplatin combinatio
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In patients receiving two lines of treatment due to progression,
the median PFS1 was 2.6 months (95% CI 2.0 to 4.9) in Arm A
and 3.6 months (95% CI 2.5 to 5.5) in Arm B (log-rank p¼0.38).
The univariate Cox HR was 0.76 (95% CI 0.51 to 1.18).
The median PFS2 was similar in the intent to treat popula-
tion: 5.03 months (95% CI 4.3 to 5.9) in Arm A and 5.8 months
(95% CI 4.3 to 7.8) in Arm B (log-rank p¼0.61) (ﬁgure 3B). The
univariate Cox HR was 0.93 (95% CI 0.70 to 1.22). When we
explored PFS2 in patients receiving two lines, the median PFS2
was 6.03 months (95% CI 5.1 to 9.0) in Arm A and 8.8 months
(95% CI 6.0 to 9.8) in Arm B (log-rank p¼0.19 and stratiﬁed
log-rank p ¼ 0.03).
DISCUSSION
The study by Burris et al
2 showing that gemcitabine provides
a clinical beneﬁt compared wiht 5FU and improves OS in
patients with advanced pancreatic cancer has established this
regimen as the standard ﬁrst-line treatment. We investigated
alternative approaches due to the lack of effective combinations
with gemcitabine when this trial was begun. Encouraging results
observed with the combination of 5FU plus cisplatin in a phase II
trial prompted the initiation of the present phase III trial.
13 The
current study shows that OS and PFS were not different in the
two arms. Moreover, gemcitabine was better tolerated when
administrated as a ﬁrst-line treatment, with signiﬁcantly fewer
cases of grade 3/4 haematological toxicity. This study conﬁrms
that gemcitabine is clearly the standard, with results in this
study even better than those in the Burris study.
This is the ﬁrst randomised phase III trial to evaluate
a chemotherapy strategy with a second line of treatment in the
treatment plan. At disease progression, the second line was
administered in 68% of patients who received ﬁrst-line LV5FU2-
CDDP treatment (Arm A) and in 55% of patients in Arm B.
Most Arm B patients received a second line of treatment for
progression (87%); in contrast, toxicity was the cause of change
in a signiﬁcant percentage of patients in Arm A (33%), and this
difference was statistically signiﬁcant. The combination of 5FU
plus cisplatin caused frequent and sometimes severe nausea and
vomiting, even when adequate prophylactic antiemetic treat-
ment was given, and these adverse side effects affected patient
compliance and explained the higher percentage of second-line
treatments in Arm A. Finally, our results do not support the role
of 5FU plus cisplatin as a ﬁrst line treatment, thus gemcitabine
remains the standard of chemotherapy. This study is consistent
with recent results published by Colucci et al
14 which showed
that gemcitabine plus cisplatin was not superior to gemcitabine
alone.
At present, there is no standard in patients with metastatic
pancreatic adenocarcinoma that progresses after gemcitabine-
based ﬁrst-line treatment. Although several phase II trials eval-
uating second-line chemotherapy can be found in the medical
literature, deﬁnitive conclusions cannot be drawn from these
results.
15e31 Oxaliplatin, a platinum-based compound, is better
tolerated than cisplatin which is active in several gastrointes-
tinal tumours. A statistically signiﬁcant increase in OS was
found in the randomised CONKO 003 phase III trial with
oxaliplatin combined with an 5FU regimen as the second line of
treatment, compared with the best supportive care.
32 A rando-
mised phase III study, presented at the annual ASCO 2008
Figure 2 Overall survival according to treatment arm (KaplaneMeier
estimation); intent to treat population. LV5FU2-CDDP arm: 5-ﬂuorouracil,
folinic acid and cisplatin combination followed by gemcitabine.
gemcitabine arm: gemcitabine followed by LV5FU2-CDDP.
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Figure 3 Progression-free survival (A) and progression-free survival in second line. (B) According to treatment arm (KaplaneMeier estimation); intent
to treat population. LV5FU2-CDDP arm: 5-ﬂuorouracil, folinic acid and cisplatin combination followed by gemcitabine. Gemcitabine arm: gemcitabine
followed by LV5FU2-CDDP.
1532 Gut 2010;59:1527e1534. doi:10.1136/gut.2010.216135
Pancreasmeeting, compared 5FU with 5FU combined with oxaliplatin
and showed a signiﬁcant increase in OS (13 vs 26 weeks;
p ¼ 0.014).
33
This is the ﬁrst controlled trial to evaluate systematic second-
line chemotherapy in patients with disease progression after the
ﬁrst line and its possible inﬂuence on OS. A high percentage of
patients (61%) were able to receive second-line chemotherapy in
this study. However, with only 69 and 55 patients in the
respective arms receiving second-line treatment, a dedicated trial
to assess speciﬁcally the efﬁcacy of second-line treatment could
be proposed.
The results seem interesting, with an OS of 8 months in the
gemcitabine then LV5FU2-CDDP arm. These results were
observed in a multicentre phase III study in unselected meta-
static patients; however, in this setting, the association of 5FU
andcisplatin may not be the best choice.
In conclusion this study did not show that LV5FU2-CDDP
was better than gemcitabine as the ﬁrst-line treatment in
advanced pancreatic cancer. No signiﬁcant difference in either
PFS or OS was observed between the two treatment arms.
Gemcitabine remains the standard for ﬁrst-line chemotherapy in
patients with unresectable metastatic tumours. A platinum-
based regimen could be used for second-line treatment and
oxaliplatin combined with 5FU seems to be the best candidate.
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